These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25799842)

  • 1. [The history of regulatory system for plasma fractionation products in the United States].
    Fukuzawa M; Tsutani K
    Yakushigaku Zasshi; 2014; 49(2):205-13. PubMed ID: 25799842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early history of regulatory requirements for poultry biologics in the United States.
    Espeseth DA; Lasher H
    Avian Dis; 2010 Dec; 54(4):1136-43. PubMed ID: 21313831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delegations of authority and organization; Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758-9. PubMed ID: 10115699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History of regulatory requirements for poultry biologics in the United States, 1970s to 1990s.
    Espeseth DA; Lasher H
    Avian Dis; 2013 Jun; 57(2):167-71. PubMed ID: 24689169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Developments in the Regulation of Biologics.
    Coleman TS
    Food Drug Law J; 2016; 71(4):544-607. PubMed ID: 29140646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological products; blood specificity designators; technical amendments--FDA. Final rule; technical amendments.
    Fed Regist; 1994 May; 59(87):23636-7. PubMed ID: 10184096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
    Schwieterman WD
    Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revision of the requirements for constituent materials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Apr; 76(71):20513-8. PubMed ID: 21491807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transmissible spongiform encephalopathy agents: concerns and responses of United States regulatory agencies in maintaining the safety of biologics.
    Asher DM
    Dev Biol Stand; 1999; 100():103-18. PubMed ID: 10616181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US FDA review and regulation of preventive vaccines for infectious disease indications: impact of the FDA Amendments Act 2007.
    Gruber MF
    Expert Rev Vaccines; 2011 Jul; 10(7):1011-9. PubMed ID: 21806396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food and Drug Administration regulations and licensure.
    Barker LF
    Fed Proc; 1975 May; 34(6):1522-4. PubMed ID: 1126452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Regulatory Evaluation of Vaccines for Human Use.
    Baylor NW
    Methods Mol Biol; 2016; 1404():773-787. PubMed ID: 27076337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine.
    Beitzel K; Allen D; Apostolakos J; Russell RP; McCarthy MB; Gallo GJ; Cote MP; Mazzocca AD
    J Knee Surg; 2015 Feb; 28(1):29-34. PubMed ID: 25268794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA may not regulate tobacco products as "drugs" or as "medical devices".
    Merrill RA
    Duke Law J; 1998 Apr; 47(6):1071-94. PubMed ID: 10557545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delegations of authority and organization; National Childhood Vaccine Injury Act of 1986--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17105-6. PubMed ID: 10125232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foreword: Follow-on Biologics: Implementation Challenges and Opportunities.
    Paradise J
    Seton Hall Law Rev; 2011; 41(2):501-10. PubMed ID: 21739728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral Drug Association statement to the Food and Drug Administration Center for Biologics Evaluation and Research on the General Biologics Licensing Regulations January 26, 1995.
    PDA J Pharm Sci Technol; 1995; 49(3):101-2. PubMed ID: 7613985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.